公开(公告)号：US20160024159A1

公开(公告)日：2016-01-28

申请号：US14773756

申请日：2014-03-12

Applicant: AMGEN INC

Inventor： Justin K. MURRAY ,  Jerry Ryan HOLDER ,  Malgorzata WANSKA ,  Christopher M. TEGLEY ,  James R. FALSEY ,  Elizabeth M. DOHERTY ,  Leslie P. MIRANDA ,  Kaustav BISWAS ,  Bin WU ,  Kelvin SHAM ,  Jason C. LONG

IPC: C07K14/435 ,  A61K38/17 ,  A61K47/48

CPC classification number: C07K14/43518 ,  A61K38/00 ,  A61K38/16 ,  A61K38/1709 ,  A61K38/1767 ,  A61K47/643 ,  A61K47/6817 ,  C07K14/435 ,  C07K14/46 ,  C07K14/47

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周受限制的NaV1.7抑制剂。 在一些公开的实施方案中，分离的多肽是NaV1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：US20140045855A1

公开(公告)日：2014-02-13

申请号：US13958478

申请日：2013-08-02

Applicant: AMGEN INC.

Inventor： Kaustav BISWAS ,  Jian J. CHEN ,  Vijay Keshav GORE ,  Scott HARRIED ,  Daniel B. HORNE ,  Matthew R. KALLER ,  Vu Van MA ,  Kelvin SHAM ,  Wenge ZHONG

IPC: C07D491/052 ,  C07D401/12

CPC classification number: C07D491/052 ,  C07D215/40 ,  C07D311/68 ,  C07D401/12 ,  C07D471/04 ,  C07D491/04

Abstract: Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

Abstract translation: 色甘酸化合物和式I的衍生物是TRPM8的有用抑制剂。 这些化合物可用于治疗多种TRPM8介导的病症和病症，并且可用于制备用于治疗这种病症和病症的药物和药物组合物。 这些疾病的实例包括但不限于偏头痛和神经性疼痛。 式I的化合物具有以下结构：其中本文提供变量的定义。

公开(公告)号：US20210108212A1

公开(公告)日：2021-04-15

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

公开(公告)号：US20190309306A1

公开(公告)日：2019-10-10

申请号：US16328221

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P3/06 ,  A61P9/10 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.